IP Library Granted Patent US 9,068,174
Granted Patent B2
US 9,068,174 · App. 13/356,776 · Granted Jun 30, 2015

Method for sensitizing tumor cells to chemotherapeutic prodrug CPT-11

Inventors: Philip M. Potter (Memphis, TN); Monika Weirdl (Memphis, TN); Matthew R. Redinbo (Chapel Hill, NC)
Assignees: St. Jude Children's Research Hospital; The University of North Carolina
C12N9/18A61K48/00C12Y301/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,068,174
App. No.
13/356,776
Granted
Jun 30, 2015
Kind
B2
Abstract

Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described.

Claims (4)

1. A method for sensitizing tumor cells to CPT-11 comprising directly injecting a tumor site comprising tumor cells with a composition comprising an isolated polynucleotide comprising a tumor-specific responsive promoter operably linked to a nucleic acid molecule encoding a mutant human carboxylesterase consisting of the amino acid sequence as set forth in SEQ ID NO: 3, wherein the tumor-specific responsive promoter is selected from the group consisting of a carcinoembryonic antigen promoter, a HER-2/neu promoter, a tumor-specific responsive promoter comprising Myc-Max response elements, and a DF3/MUC promoter, so that said tumor cells express the mutant human carboxylesterase and are sensitized to CPT-11.

2. A method of inhibiting tumor cell growth comprising:

(a) sensitizing tumor cells in accordance with the method of claim 1 ; and

(b) contacting said sensitized tumor cells with a chemotherapeutic prodrug so that tumor cell growth is inhibited, wherein said chemotherapeutic prodrug is CPT-11.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 14, 2020
From: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052166/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2012
From: POTTER, PHILIP M.; WIERDL, MONIKA
To: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Reel/Frame 027589/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2012
From: REDINBO, MATTHEW R.
To: THE UNIVERSITY OF NORTH CAROLINA
Reel/Frame 027589/0746 →
Continuity (4)
Division 13020871 · Feb 4, 2011
Division 12306031
Provisional Application 60805643 · Jun 23, 2006
Related Publication 20120142108A1 · Jun 7, 2012